Clinical Trials Logo

Carcinoma, Hepatocellular clinical trials

View clinical trials related to Carcinoma, Hepatocellular.

Filter by:

NCT ID: NCT03534843 Completed - Clinical trials for Hepatocellular Carcinoma

A Comparison Between Child-Pugh and Albumin-Bilirubin Scores

Start date: January 1, 2005
Phase:
Study type: Observational

To compare Child-Pugh and Albumin-Bilirubin scores in patients with spontaneous rupture of hepatocellular carcinoma

NCT ID: NCT03533920 Completed - Clinical trials for Hepatocellular Carcinoma Non-resectable

Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma

Start date: October 25, 2017
Phase: N/A
Study type: Interventional

Pivotal Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma

NCT ID: NCT03520257 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

The Study of Apatinib Plus Radiotherapy vs. Apatinib in the Treatment of Hepatocellular Carcinoma With BCLC-C Stage I and Stage II Portal Vein Tumor Thrombus

Start date: May 1, 2018
Phase: Phase 2
Study type: Interventional

This study uses to suppress the growth of tumors, extend the patient's survival time and improve the quality of life as much as possible. Through the treatment, the patient is given the chance to undergo surgical resection, thereby more effectively prolonging the OS. Apatinib is a small-molecule VEGFR tyrosine kinase inhibitor. It mainly treats malignant tumors by inhibiting VEGFR and exerting anti-angiogenic effects. Preclinical studies have shown that its anti-tumor effect is better than that of the similar drug PTK787. Phase II studies of hepatocellular carcinoma have initially demonstrated the effectiveness and safety of apatinib in the treatment of advanced HCC. Radiotherapy of tumors and portal vein tumor thrombi can promote further tumor shrinkage, and at the same time, the physiological basis for the recanalization of the original tumor thrombus itself will result in necrosis and fibrosis of the tumor thrombus, completely blocking the blood supply to the tumor portal vein. As a result, blood supply to the other side of the portal vein increases, and hepatocyte regeneration in a healthy liver is promoted, so that the patient can obtain surgical opportunities. Based on the therapeutic potential of apatinib and radiotherapy, we designed a prospective exploratory clinical study of this patient with advanced liver cancer.

NCT ID: NCT03519997 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma

Start date: April 26, 2018
Phase: Phase 2
Study type: Interventional

This is a non-randomized, open-label, multi-site phase II therapeutic trial of pembrolizumab and bavituximab in patients with locally advanced HCC. Locally advanced or metastatic HCC is defined as disease that is not amenable to surgical and/or locoregional therapies. Subjects must not have received prior systemic therapy for advanced HCC in keeping with the first-line setting of this study.

NCT ID: NCT03518502 Recruiting - Clinical trials for Hepatocellular Carcinoma

Sorafenib Monotherapy vs. TACE-sorafenib Sequential Therapy for HCC With Metastasis

Start date: March 1, 2012
Phase: Phase 4
Study type: Interventional

Sorafenib is the standard therapy for hepatocellular carcinoma (HCC) with extrahepatic metastasis (EHM). However, addition of transarterial chemoembolization (TACE) may be beneficial for controlling intrahepatic tumour. The investigators aimed to compare the efficacy between the sorafenib monotherapy and TACE-sorafenib sequential therapy in HCC patients with EHM.

NCT ID: NCT03517332 Recruiting - Breast Cancer Clinical Trials

Circulating Tumor DNA Exposure in Peripheral Blood

Start date: January 1, 2015
Phase:
Study type: Observational

This is a prospective, multi-center, blinded feasibility study. The objective of this study is to test the feasibility of the detection of tumor DNA of a variety of tumors in peripheral blood using a novel process for the detection of circulating tumor DNA (ctDNA).

NCT ID: NCT03516890 Completed - Clinical trials for Hepatocellular Carcinoma

Management of Spontaneous Ruptured Hepatocellular Carcinoma

Start date: January 1, 2005
Phase:
Study type: Observational

To investigate the best treatment for hepatocellular carcinoma rupture

NCT ID: NCT03516448 Enrolling by invitation - Clinical trials for Hepatocellular Carcinoma

Expanding Phase III Study of Tyroserleutide for Injection

Start date: March 24, 2016
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blinded, placebo-controlled, multi-center Clinical Trial. Patients with no tumor lesions 21 days after resection of hepatocellular carcinoma will be randomized in a 1:1 ratio to 1 of the 2 treatment groups:6mg/d Tyroserleutide (injection), or placebo

NCT ID: NCT03516071 Completed - Clinical trials for Hepatocellular Carcinoma (HCC)

A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC

Start date: May 17, 2017
Phase: Phase 2
Study type: Interventional

This is a Phase 2, Open-label, Randomized, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Brivanib in Patients with Previously Treated Advanced Hepatocellular Carcinoma.

NCT ID: NCT03515369 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Effect of Babaodan on Tumor Recurrence After Curative Resection of Hepatocellular Carcinoma

Start date: May 2018
Phase: Phase 4
Study type: Interventional

The aim of this study is to evaluate the effect of traditional Chinese medicine Babaodan on tumor recurrence of hepatocellular carcinoma after curative resection, as well as the safety of this treatment